FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1050-1051 September 6, 2007 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Hudes, G. PubMed Citation

To the Editor: Hudes et al. (May 31 issue)¹ suggest the use of temsirolimus as first-line treatment for metastatic renal-cell carcinoma. On the basis of their trial, temsirolimus was the second new drug to receive Food and Drug Administration (FDA) approval, after sunitinib,² in that setting. We think that temsirolimus should be the preferred drug in patients with metastatic renal-cell cancer and a poor performance status. The authors' conclusions, however, do not account for subgroups, and the FDA allows the use of both temsirolimus and sunitinib as first-line therapy. How can physicians choose between the two treatments?

Nicola Fazio, M.D.
. . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.